Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 1/20 | 0.66 |
| ▸ | PLAU | P00749 | 1/20 | 0.66 |
| ▸ | NCF1 | P14598 | 1/20 | 0.66 |
| ▸ | NOS3 | P29474 | 1/20 | 0.66 |
| ▸ | NOS1 | P29475 | 1/20 | 0.66 |
| ▸ | NOS2 | P35228 | 1/20 | 0.66 |
| ▸ | BACE1 | P56817 | 1/20 | 0.66 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344467 | 0.82 | TLR8 (0.46) | F12PLAUNCF1NOS3NOS1 | |
| SCHEMBL29377365 | 0.81 | PLAU (1.00) | F12PLAUNCF1NOS3NOS1 | |
| SCHEMBL49220 | 0.81 | PLAU (1.00) | F12PLAUNCF1NOS3NOS1 | |
| SCHEMBL28116864 | 0.79 | PLAU (0.95) | F12PLAUNCF1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL509104 | 0.79 | PLAU (0.95) | F12PLAUNCF1NOS3NOS1 | |
| Iodide SCHEMBL29988059 | 0.79 | PLAU (0.95) | F12PLAUNCF1NOS3NOS1 | |
| SCHEMBL27667726 | 0.77 | ALDH1A1 (0.61) | TLR8HTR1BMEN1ALDH1A1KMT2A | |
| Naphthalene SCHEMBL5965913 | 0.75 | DNM1 (0.57) | TLR8MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL14853049 | 0.75 | TLR8 (0.50) | TLR8HTR1BKDM4EMEN1ALDH1A1 | |
| Naphthalene SCHEMBL11586730 | 0.73 | DNM1 (0.62) | TLR8MEN1ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1773817-B1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | F12 582/4885PLAU 886/4885NCF1 1793/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | F12 124/4885PLAU 2462/4885NCF1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.